September 25, 2024

Publication as a result of collaboration with Kyoto University

Kanagawa, Japan - FIMECS, Inc. ("FIMECS"), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announces that the results of research collaboration with Kyoto University has been published in Cells published by Multidisciplinary Digital Publishing Institute (MDPI, Switzerland) on September 19, 2024.

Title: α-Parvin Expression in Breast Cancer Tissues: Correlation with Clinical Parameters and Prognostic Significance

Authors: Midori Takeda, Hiroaki Ito, Keisuke Kitahata, Sota Sato, Akira Nishide, Kanae Gamo, Shunsuke Managi, Tohru Tezuka, Akihiko Yoshizawa and Minsoo Kim

DOI: doi.org/10.3390/cells13181572

In collaboration with Dr. Kim Minsoo, Associate Professor at Kyoto University, Graduate School of Medicine, we focused on cancer research by utilizing our platform, RaPPIDS™. This paper examines the association between α-Parvin associated with focusing protein, integrin-linked kinase (ILK) of this collaboration and in breast cancer and is an important result showing disease relevance.

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently 'undruggable' targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS™

RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company's proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

# # #

FIMECS, Inc. Media and Investor Contact:

FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com